Homo genome - Company finances
|
EUR
|
2018
From: 2018-01-01
To: 2018-12-31
|
2019
From: 2019-01-01
To: 2019-12-31
|
2020
From: 2020-01-01
To: 2020-12-31
|
2021
From: 2021-01-01
To: 2021-12-31
|
2022
From: 2022-01-01
To: 2022-12-31
|
2023
From: 2023-01-01
To: 2023-12-31
|
2024
From: 2024-01-01
To: 2024-12-31
|
2025
From: 2025-01-01
To: 2025-12-31
|
|---|---|---|---|---|---|---|---|---|
|
Financial data
|
||||||||
| Sales revenue | 40,395 | 85,530 | 76,780 | 83,580 | 90,080 | 93,480 | 104,280 | 95,990 |
| Profit before tax | - | - | - | - | - | - | - | - |
| Net profit | -17,225 | 13,486 | 12,694 | 18,838 | 20,569 | 26,592 | 27,267 | 24,687 |
| Equity | -14,793 | -1,307 | 11,387 | 30,225 | 50,794 | 71,975 | 99,242 | 123,929 |
| Liabilities | 554,851 | 506,303 | 469,649 | 417,731 | 365,901 | 302,170 | 231,250 | 180,829 |
| Non-current assets | 528,888 | 491,555 | 454,222 | 416,888 | 379,555 | 357,778 | 320,444 | 283,111 |
| Current assets | 11,170 | 13,441 | 26,881 | 31,124 | 37,190 | 16,218 | 9,884 | 21,633 |
| Total assets | 540,058 | 504,996 | 481,103 | 448,012 | 416,745 | 373,996 | 330,328 | 304,744 |
|
Taxes paid
|
||||||||
| STI taxes | - | - | - | - | - | 12,795 | 10,017 | 10,544 |
|
Financial indicators
|
||||||||
| Revenue change y/y | - | +111.7% | -10.2% | +8.9% | +7.8% | +3.8% | +11.6% | -7.9% |
| ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. | -3.2% | 2.7% | 2.6% | 4.2% | 4.9% | 7.1% | 8.3% | 8.1% |
| ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. | - | - | 111.5% | 62.3% | 40.5% | 36.9% | 27.5% | 19.9% |
| Profit margin Net profit margin. Shows the overall profitability of the company. | -42.6% | 15.8% | 16.5% | 22.5% | 22.8% | 28.4% | 26.1% | 25.7% |
| EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. | - | - | - | - | - | - | - | - |
| Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. | - | - | 41.2 | 13.8 | 7.2 | 4.2 | 2.3 | 1.5 |
| Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. | 40,395 | 85,530 | 76,780 | 83,580 | 90,080 | 93,480 | 104,280 | 95,990 |
Sales revenue
See Scoris data in Google Search
Mark Scoris as a favorite source. One click, no registration.
Homo genome - Social security debts
| From | To | Debt, € |
|---|---|---|
| 2026-08-19 | 2026-08-19 | 8.48 |
| 2024-12-17 | 2024-12-20 | 8.43 |
Homo genome - VMI tax arrears
The company had no tax arrears (debts) to the State Tax Inspectorate
VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.
Analysis of the company's financial position
This description was generated by artificial intelligence.
Report if inaccurate.
Homo genome, UAB (company code 302781230) is a Private Limited Liability Company engaged in rental and operating of own or leased real estate. In 2025, the company generated revenue of €96.0K and net profit of €24.7K, resulting in a profit margin of 25.7%. Revenue declined by 8.0% year on year, but remained slightly above the 2023 level, giving a modest 2-year increase of 2.7%. Profitability was broadly stable over the period, with net profit of €26.6K in 2023 and €27.3K in 2024 before easing in 2025. The balance sheet continued to strengthen: equity increased from €72.0K in 2023 to €123.9K in 2025, while liabilities fell from €302.2K to €180.8K. Total assets declined from €374.0K to €304.7K, with long-term assets representing the largest share. In 2025, ROE was 19.9%, ROA 8.1%, debt-to-equity 1.46, and asset turnover 0.31x. Revenue per employee was €96.0K and profit per employee €24.7K.